Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8<sup>+</sup> T cell cytolytic killing of melanoma cells.

Shaw, Gary; Cavalcante, Ludimila; Giles, Francis J; Taylor, Alison

Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8⁺ T cell cytolytic killing of melanoma cells.

Shaw, Gary; Cavalcante, Ludimila; Giles, Francis J; Taylor, Alison.

Afiliação

Shaw G; School of Medicine, Leeds Institute of Medical Research, University of Leeds, Wellcome Trust Brenner Building, St James's University Hospital, Leeds, LS9 7TF, UK.
Cavalcante L; Winship Cancer Institute of Emory, University School of Medicine, Atlanta, GA, USA.
Giles FJ; Developmental Therapeutics LLC, Chicago, IL, USA.
Taylor A; School of Medicine, Leeds Institute of Medical Research, University of Leeds, Wellcome Trust Brenner Building, St James's University Hospital, Leeds, LS9 7TF, UK. a.taylor1@leeds.ac.uk.

J Hematol Oncol ; 15(1): 134, 2022 09 14.

Article em En | MEDLINE | ID: mdl-36104795

Assuntos

Proteínas de Checkpoint Imunológico; Melanoma Experimental; Animais; Linfócitos T CD8-Positivos; Estudos Clínicos como Assunto; Quinase 3 da Glicogênio Sintase; Glicogênio Sintase Quinase 3 beta; Melanoma Experimental/tratamento farmacológico; Camundongos; Inibidores de Proteínas Quinases; Receptores Imunológicos

Palavras-chave

9-ING-41; Elraglusib; Glycogen synthase kinase-3; LAG-3: lymphocyte activation gene-3; Melanoma; PD-1: programmed cell death protein 1; T cells; TIGIT: T cell immunoreceptor with immunoglobulin and ITIM domains; Tbet/Tbx21

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Melanoma Experimental / Proteínas de Checkpoint Imunológico Limite: Animals Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google